Most Read Articles
Yesterday
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 2 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Christina Lau, 6 days ago

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.

Take metformin before meals to improve triglyceride control, study suggests

19 Feb 2019

Preprandial administration of metformin successfully and safely reduces postprandial plasma triglyceride levels, a new study has shown.

Eleven patients (mean age 53.5±12.9 years; nine men) were randomly assigned to receive metformin either 30 minutes before a test meal or 15 minutes after. A meal test, involving cookies containing 75 g of carbohydrate, was performed to investigate the difference in effect between preprandial and postprandial administration of metformin on postprandial hypertriglyceridaemia.

The mean body mass index (BMI) was 27.9 kg/m2, while the mean nonfasting plasma triglyceride concentration was 275.9±189.0 mg/dL. Eight participants were given 750 mg of single-dose metformin, while the remaining three received a single 500-mg dose.

Relative to postprandial administration, taking metformin before the meal test resulted in slightly lower postprandial triglyceride levels. The area under the curve for the 0–4-hour concentration of triglycerides was significantly lower in the pre- vs postprandial administration protocol (p=0.032).

Blood glucose levels also tended to be reduced in the first 180 minutes after meal test, but was significantly elevated in the preprandial protocol at 240 minutes (p=0.048).

Using a visual analogue scale, participants in the preprandial metformin protocol reported significantly increased meal satiety compared with those who were given the medication after the meal test (p=0.036). There were no significant between-group differences in terms of negative gastrointestinal symptoms, such as heartburn and stomach heaviness.

The present findings indicate that simply changing the timing of metformin medication may improve triglyceride control among type 2 diabetes mellitus patients, said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Yesterday
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 2 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Christina Lau, 6 days ago

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.